article Open AccessTop 1% cited

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

New England Journal of Medicine · 2008 · Vol. 358(24) · pp. 2560–2572

Anushka Patel(The University of Sydney)Anushka Patel(The University of Sydney)Stephen MacMahon(The University of Sydney)John Chalmers(The University of Sydney)Bruce Neal(The University of Sydney)Laurent Billot(The University of Sydney)Mark Woodward(Université Paris Cité)Michel MarreMark E. Cooper(The University of Queensland)Paul Glasziou(Utrecht University)Diederick E. Grobbee(Université de Montréal)Pavel Hamet(The University of Melbourne)Stephen Harrap(University of Sheffield)Simon Heller(Hypertension Institute)Lisheng Liu(IRCCS Istituto Auxologico Italiano)Giuseppe Mancia(Aarhus University)C. E. Mogensen(Chinese General Hospital College of Nursing and Liberal Arts)Changyu Pan(St Mary's Hospital)Neil R Poulter(University of Auckland)Anthony Rodgers(University of Leicester)Bryan Williams(The George Institute for Global Health)Séverine Bompoint(Radboud University Nijmegen)Bastiaan E. de Galan(The University of Sydney)Rohina Joshi(Université Paris Cité)

View via DOI Full-text PDF

Abstract

A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy. (ClinicalTrials.gov number, NCT00145925.)

Diabetes Treatment and Management Blood Pressure and Hypertension Studies Diabetes, Cardiovascular Risks, and LipoproteinsMedicineHazard ratioGlycated hemoglobinInternal medicineType 2 diabetesRetinopathyNephropathyDiabetes mellitusDiabetic retinopathyAlbuminuria

MeSH terms

AgedBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic AngiopathiesDiabetic NephropathiesDrug Therapy, CombinationFemaleFollow-Up StudiesGliclazideGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsMale